HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miranda-Carús, M.-E. Articles by Martín-Mola, E. Search for Related Content PubMed PubMed Citation Articles by Miranda-Carús, M.-E. Articles by Martín-Mola, E.

IL-15 and the Initiation of Cell Contact-Dependent Synovial Fibroblast-T Lymphocyte Cross-Talk in Rheumatoid Arthritis: Effect of Methotrexate¹

Department of Rheumatology, Hospital Universitario La Paz, Paseo de La Castellana, Madrid, Spain

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
To characterize the molecules responsible for synovial fibroblast-T lymphocyte (TL) cross-talk in rheumatoid arthritis (RA), synovial fibroblasts from patients with established RA (RASFibs) were cocultured with TLs from peripheral blood of early RA patients (RAPBTL). TLs from peripheral blood of healthy controls and from synovial fluid of RA served as controls. Adhesion molecules and cytokines were determined by flow cytometry, ELISA, and real-time PCR. RAPBTL (n = 20) induced an up-regulation of ICAM-1, intracellular IL-8, IL-6, IL-15, and surface IL-15 in cocultured RASFibs. In turn, RAPBTL showed an up-regulation of TNF-, IFN-, IL-17, CD25, and CD69 expression. Responses seen with TLs from peripheral blood of healthy controls (n = 20) were significantly lower, whereas responses with TLs from synovial fluid of RA (n = 20) were maximal. Blocking Abs to IL-15 and CD54, but not an isotype-control Ab, down-regulated the increased TL cytokine and activation marker expression. Abs to CD69, CD11a, IL-17, TNF-, and IFN- significantly decreased the up-regulation of RASFib cytokine and CD54 expression. Cocultures using 0.4-µm inserts did not result in up-regulation of surface molecules or cytokines. Methotrexate significantly inhibited RASFib/TL cross-talk signals and decreased adhesion of TL to RASFibs. In summary, RASFib production of IL-15 induces the proinflammatory cytokines TNF-, IFN-, and IL-17 in cocultured TLs through a cell contact-dependent mechanism. In turn, these cytokines stimulate the expression of IL-15, IL-8, and IL-6 in RASFibs, thereby creating a feedback loop that favors persistent synovial inflammation. Methotrexate seems to disrupt this loop by decreasing cell adhesion.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
The hallmark of rheumatoid arthritis (RA)³ is an aggressive proliferation of the synovial membrane that results in progressive joint damage. The high proliferative rate and erosive activity of RA synovial fibroblasts (RASFibs) have long been attributed to macrophage-derived cytokines such as TNF- and IL-1 (1); in addition, immortalizing mutations of synovial fibroblasts have been invoked (1). The role of T lymphocytes (TLs) in initiating and perpetuating RA has been controversial because a triggering Ag has not been identified, the majority of synovial T cells are polyclonal, IL-2 levels in the RA synovium are low, and only a small fraction of synovial T cells express IL2-R (2). It is assumed that TLs in the RA synovium can interact with professional APCs (3); in addition, direct interactions between TLs and RASFibs might be important contributors to the chronic RA inflammation (4).

In vitro, T cells modulate fibroblast proliferation and secretion of matrix proteins (5, 6, 7). Highly purified resting T cells, in the absence of T cell mitogens, have been reported to activate synovial fibroblasts (SFibs) in vitro as assessed by induction or augmentation of stromelysin, IL-6, IL-8, and PGE at mRNA and/or protein levels (8). In turn, SFibs are able to modify lymphocyte biology (9): isolated TLs rapidly undergo programmed cell death, whereas coculture with RASFibs prevents apoptosis (10, 11), and it has recently been reported that RASFibs induce proliferation of T cells upon long-term coculture (12).

SFibs constitutively express IL-15 (13, 14), a cytokine that shares many properties with IL-2 (13). IL-15 acts through a heterotrimeric receptor consisting of a specific high-affinity binding -chain (designated as IL-15R) plus the IL2R - and common -chain, which are responsible for signaling (15, 16). IL-15 can activate TLs in the absence of Ag (17). This cytokine-driven or "bystander" activation of T cells occurs in vivo independently of MHC-TCR interactions (18). IL-15, in contrast with IL-2, is expressed on the surface of monocytes and of fibroblasts, where it can exert biological functions through cell contact-dependent mechanisms (13). Fibroblasts from human spleen have been described to regulate NK cell differentiation from blood CD34⁺ progenitors via cell surface IL-15 (19), and surface IL-15 on TNF--stimulated dermal fibroblasts induces proliferation of activated T cells (20).

IL-15 has been detected in synovial fluid (21), synovial membrane (21), and serum (22) of RA patients. In addition, in vitro (21, 23) and in vivo studies (24, 25) suggest that IL-15 may be a major player in the pathogenesis of RA. IL-15-recruited and activated TLs in the synovial membrane promote TNF- secretion from synovial macrophages (23). Administration of soluble IL-15R prevents collagen-induced arthritis in mice and effectively reduces inflammation, synovial hyperplasia, and bone erosions (24). In addition, a phase I clinical trial in humans using a fully human anti-IL-15 mAb suggests that neutralization of IL-15 in patients with RA is effective and safe (25).

Our working hypothesis was that IL-15 on the surface of RASFibs is able to modulate TL cytokine secretion through direct cell contact in the absence of local Ag recognition. These polyclonal IL-15-activated T cells would in turn stimulate synovial fibroblasts, thereby creating a juxtacrine loop favoring persistent inflammation. Our early arthritis clinic allowed the study of T cells from early RA patients who had not received disease-modifying antirheumatic drugs or steroids, thereby minimizing interference of drugs with in vitro TL responses.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Patients

Synovial membranes were obtained from 10 RA patients undergoing synovectomy or arthroplasty and from 10 osteoarthritis (OA) patients undergoing arthroplasty. Synovial fluid was obtained from 20 patients with established RA who were receiving treatment with oral methotrexate (MTX) and low-dose prednisone. Peripheral blood was obtained from 20 healthy controls and from 20 early RA patients fulfilling at least four American College of Rheumatology criteria (26), who had never received disease-modifying drugs or corticosteroids and with a disease duration of <6 mo. La Paz University Hospital in Madrid, Spain, has a monographic clinic that takes care of early arthritis patients referred from a wide primary care area. This facilitated recruitment of untreated early RA patients for the present study. Among early RA patients there were 7 male and 13 female, 15 (75%) tested positive for IgM rheumatoid factor, their ages were 18–80 years (mean 51.42, SD 18.53, median 50), duration of symptoms at first evaluation was from 2 to 26 wk (mean 11.53, SD 7.6, median 10), and disease activity score 28 (DAS28) (27) at first evaluation was from 4.71 to 7.49 (mean 5.98, SD 0.78, median 5.84). The study was approved by the Hospital Ethics Committee.

Culture of human fibroblasts

RASFibs and OASFibs were obtained by collagenase digestion (type I; Worthington Biochemical, Freehold, NJ) of human synovial tissue obtained at arthroplasty or synovectomy. Dermal fibroblasts were obtained by collagenase digestion of normal skin obtained from punch biopsies of five healthy volunteers. Cells were plated in 75-cm² flasks and grown in RPMI 1640 medium (Invitrogen Life Technologies, Grand Island, NY) supplemented with 10% FCS (Invitrogen Life Technologies), 2 mM L-glutamine, 50 U/ml penicillin, and 50 µg/ml streptomycin (Invitrogen Life Technologies). Cells were passaged at dilution 1/2 when reaching 95% confluence, by gentle trypsinization (0.05% trypsin/0.53 mM EDTA; Invitrogen Life Technologies). Fibroblasts were used between passages 3 and 5. At this time, they appeared to be a homogeneous population of fibroblast-like cells that stained positive with anti-Thy-1 (CD90) Ab (28) and were negative for the expression of CD1, CD3, CD19, CD14, CD80, and CD86, as determined by flow cytometry and fluorochrome-conjugated mAbs (BD Pharmingen, San Diego, CA).

TL purification

PBMCs were separated by Ficoll-Hypaque (Amersham, Uppsala, Sweden) density gradient centrifugation from 1) peripheral blood TLs from early RA patients (RAPBTL; n = 20); 2) peripheral blood TLs from healthy controls (HCPBTL; n = 20), and 3) synovial fluid TLs from RA patients (RASFTL) receiving treatment with oral pulse low-dose MTX (7.5–15 mg/wk) and low-dose prednisone (5–7.5 mg/day) (n = 20). Highly purified TLs were prepared from PBMCs by exhaustive immunomagnetic negative selection in an Automacs (Miltenyi Biotec, Bergisch Gladbach, Germany) using a T cell negative isolation kit (Miltenyi Biotec). The purity of the TL preparation was >99% CD3-positive by flow cytometry. Functional purity was assessed by the lack of proliferative responses to superantigens, lectins, and/or soluble anti-CD3.

Coculture conditions

Because in many cell systems collagen and cytokine production vary with the stage of cell growth (29, 30), experiments were performed with confluent fibroblast cultures prepared 24 h before contact. All experimental conditions were performed in duplicate and variation between replicates was <5%. Fibroblasts were seeded in six-well plates at 3 x 10⁵ cells/well. Twenty-four hours later, the separated TLs (2 x 10⁶ cells/well) were added, and cells were harvested after 6, 24, 48, 72, 96, and 120 h. TLs were collected by thorough washing with cold, serum-free medium. Subsequently, fibroblasts were detached with Trypsin-EDTA (Invitrogen Life Technologies). For detection of surface IL-15, fibroblasts were detached on ice with cold 5 mM EDTA in PBS.

In preliminary experiments, increasing TL numbers (T cells: 1 x 10⁶, 2 x 10⁶, 3 x 10⁶, 4 x 10⁶, and 5 x 10⁶ per well) were tested in coculture. A dose-response effect was observed, and 2 x 10⁶ TLs were used because an adequate amount of cytokine was induced to allow meaningful comparisons without using an excess of T cells. With TL numbers above 3 x 10⁶ per well, the observed TL responses were lower. This may be explained by a poor stechiometric proportion between TL number and fibroblast-derived cytokines.

Transwell system

A six-well Transwell system (Corning Costar, Cambridge, MA) was used to conduct some coculture experiments. The system consists of two compartments: a top well with a porous matrix (0.4 µm) and a bottom well. This setup allows coculture of two types of cells to grow in the same medium with soluble factors exchanged through the pores, while preventing direct contact between them. RASFibs were grown to confluence in the bottom well, and TLs were added either to the same well-allowing contact or in the top well-avoiding contact.

Paraformaldehyde (PFA) fixation of cells

Confluent fibroblasts in six-well plates were fixed on ice with chilled 2% PFA for 10 min. Subsequently, cells were thoroughly washed with chilled PBS to eliminate any traces of PFA before starting coculture.

Inhibition of cytokine and surface molecule up-regulation by neutralizing mAbs

Neutralizing mAbs against IL-15 (R&D Systems, Abingdon, U.K.), IL-2/IL15R (CD122), CD54 (R&D Systems), HLA class I (clone W6/32; Sigma-Aldrich, St. Louis, MO), or isotype control (BD Pharmingen) were incubated at 10 µg/ml with RASFibs for 30 min at 4°C. TLs were subsequently added without washing RASFibs. A neutralizing polyclonal goat IgG anti-IL-15R Ab (R&D Systems) or control goat IgG were used at 1 µg/ml. A recombinant human IL-15R/Fc chimera (R&D Systems) or control human IgG were used at 100 ng/ml. Alternatively, neutralizing mAbs against CD11a/LFA-1, CD 69 (BD Pharmingen), TNF-, IFN-, IL-17 (R&D Systems), or an isotype control mAb of irrelevant specificity (BD Pharmingen) were incubated at 10 µg/ml with TLs for 30 min at 4°C. TLs were then added without washing to RASFibs. Percent inhibition was calculated as follows: 100 – [(cytokine/surface marker expression with neutralizing Ab present)/(cytokine/surface marker expression without neutralizing Ab present)] x 100.

In vitro treatment with MTX

RASFibs were pretreated with MTX (1–500 nM; Sigma-Aldrich) 4 h before starting cocultures. Subsequently, TLs were added as described, without washing away MTX. In some conditions, and to determine the contribution of adenosine release to the effect of MTX, adenosine deaminase (ADA; Type IV, calf intestinal, 0.125 IU/ml; Sigma-Aldrich), the adenosine A2 receptor antagonist 3,7-dimethyl-1-propargylxanthine (DMPX; 10 µM; Sigma-Aldrich), or the adenosine A1 receptor antagonist 8-cyclopentyl-dipropylxanthine (DPCPX; 10 µM; Sigma-Aldrich) were added to the medium together with MTX. ADA was dialyzed against PBS overnight (4°C) before use, as described (31).

Percent inhibition by MTX was calculated as follows: 100 – [(cytokine/surface marker expression with MTX present)/(cytokine/surface marker expression without MTX treatment)] x 100.

TL adherence to synovial fibroblasts (heterotypic adherence)

The number of TLs that were firmly adhered to RASFibs was determined in 96-h cocultures, with and without MTX present. Adherent TLs were counted as described by Gadangi et al. (31): the nonadherent TLs were removed by thorough washing with cold PBS. RASFib cultures, with their adherent TLs, were fixed with 4% PFA. The fixed cells were observed under an inverted microscope, and the number of adherent TLs was counted in three separate sites per well. All conditions were studied in triplicate. Percent inhibition of adhesion by MTX was calculated as follows: 100 – [(number of adhered TL with MTX present)/(number of adhered TL without MTX present)] x 100.

In vivo effect of treatment

Five patients with early RA donated blood for a second time, once disease activity had been controlled. Blood was also obtained from the five healthy subjects who had previously acted as controls for these patients. The patients were receiving oral MTX 15 mg weekly, except for one patient who was taking 25 mg per week. In addition, all five patients except for one were taking prednisone, 2.5 mg daily. IgM rheumatoid factor was positive at initial evaluation in four of these five patients. There were two male and three female; ages were 39.6 ± 13.83 (mean ± SD). DAS28 before initiation of treatment was 5.53 ± 0.76 (mean ± SD) and at the time of second blood drawing it was 1.95 ± 0.4. These patients were in remission as defined by a DAS28 score below 2.6 (32).

Cocultures of RAPBTL/RASFib and HCPBTL/RASFib were established. To minimize experimental variability, the same fibroblast lines were used for experiments with RAPBTL before and after treatment. Expression of cytokines, adhesion molecules, and activation markers in RAPBTL, HCPBTL, and RASFib were determined by flow cytometry in 96-h cocultures. Results were compared for each patient with results obtained before initiation of treatment. Percent inhibition was calculated as follows: 100 – [(cytokine/surface marker expression before starting MTX)/(cytokine/surface marker expression at disease control with MTX)] x 100.

Results were compared for each healthy control with results obtained at initial experiment. For healthy controls, percent variation was calculated as follows: 100 – [(cytokine/surface marker expression at initial experiment)/(cytokine/surface marker expression at "disease control" experiment)] x 100.

Intracellular cytokine staining, surface staining, and flow cytometry

For intracellular cytokine staining, RASFibs and TLs were cocultured as described, and 10 µg/ml brefeldin A (Sigma-Aldrich) was added for the last 6 h. Importantly, no brefeldin A was added for detection of intracellular IL-15 as opposed to other intracellular cytokines. RASFibs and TLs were harvested, washed with PBS/2% FCS/0.01% NaN₃, permeabilized for 10 min with FACS permeabilizing solution 2 (BD Pharmingen), washed again, and incubated with various cytokine-specific mAbs or isotype-matched control mAbs conjugated to fluorochrome for 30 min at room temperature. After washing once with PBS/2% FCS/0.01% NaN₃ and once with PBS, cells were resuspended in 1% PFA and analyzed in a FACScan flow cytometer using CellQuest software (BD Biosciences, Mountain View, CA). Cells were analyzed by gating based on forward and 90° light scatter plus specific staining with anti-CD90 mAb (fibroblasts; BD Pharmingen) or anti-CD3 mAb (TLs; BD Pharmingen).

Anti-CD90 (FITC), anti-IL-6 (PE), anti-IL-8 (PE), anti-CD3 (PerCP), anti-TNF- (PE), and anti-IFN- (FITC) were obtained from BD Pharmingen. FITC-conjugated anti-IL-15 was from R&D Systems. Purified monoclonal anti-IL-17 was from R&D Systems and was conjugated to FITC using a kit from Pierce (Rockford, IL) according to the manufacturer’s instructions. For surface staining, brefeldin A and the permeabilization step were omitted. FITC-labeled anti-CD25, anti-CD11a, anti-HLA-DR, and anti-CD40L and PE-labeled anti-CD54, anti-CD69, and anti-CTLA-4 were from BD Pharmingen.

Results are expressed as percent positive cells for each cytokine/surface molecule referred to staining with isotype control Ab. In addition, mean fluorescence intensity (MFI) values are given as the difference between the MFI of tested cells and the MFI of background staining. Fluorescence stimulation index was calculated as the ratio (MFI of the cocultured cells)/(MFI of the resting cells).

ELISAs

RASFibs and TLs were cocultured under conditions identical with those described above, except that brefeldin A was omitted. Cell-free supernatants were collected and stored at –80°C. ELISAs for IL-15, IL-6, IL-8, TNF-, IFN-, and IL-17 were performed using DuoSet kits (R&D Systems), following the manufacturer’s instructions.

Quantitative RT-PCR

For RNA extraction, RASFibs and TLs were collected as described above. A population of TLs that remained attached to RASFibs despite extensive washing was detected. Treatment with trypsin detached RASFibs from the culture plates and at the same time was able to dissociate the remaining adherent TLs. For RASFib mRNA extraction, the resulting SFib/TL suspension was treated with a magnetically labeled anti-CD3 mAb (Miltenyi Biotec) and was passed through an Automacs (Miltenyi Biotec). Flow cytometric and mRNA analyses of those TLs that were strongly adherent to RASFibs demonstrated that there was no significant difference in cytokine or surface molecule expression with nonattached TLs, suggesting that direct contact between RASFibs and TLs is a dynamic process.

Total cellular RNA was isolated using the RNeasy mini kit (Qiagen, Hilden, Germany) with in-column DNase treatment. For each sample, 1 µg of total RNA was subjected to reverse transcription using the Advantage RT for PCR kit (BD Clontech, Palo Alto, CA) according to the manufacturer’s instructions. Aliquots (1 µl) of the reverse transcription products were used for quantitative PCR in the LightCycler PCR and Detection System (Roche Molecular Biochemicals, Mannheim, Germany) using the FastStart DNA Master SYBR Green I kit (Roche Diagnostics) as described by the manufacturer. The PCRs were set up in microcapillary tubes in a volume of 20 µl. The following sense and antisense primers were used: IL-6 sense, 5'-CAG CTA TGA ACT CCT TCT CCA CAA GC-3'; IL-6 antisense, 5'-CTG AGA TGC CGT CGA GGA TGT ACC G-3' (product size, 201); IL-8 sense, 5'-ATG ACT TCC AAG CTG GCC GTG GCT-3'; IL-8 antisense, 5'-TCT CAG CCC TCT TCA AAA ACT TCT C-3' (product size, 292); IL-15 sense, 5'-ATG AGA ATT TCG AAA CCA CAT-3'; IL-15 antisense, 5'-CTC CAA GAG AAA GCA CTT C-3' (product size, 282); TNF- sense, 5'-ATG AGC ACT GAA AGC ATG ATC CGG-3'; TNF- antisense, 5'-CTA CAA CAT GGG CTA CAG GCT TGT-3' (product size, 280); IFN- sense, 5'-TGC AGG TCA TTC AGA TGT AG-3'; IFN- antisense, 5'-AGC CAT CAC TTG GAT GAG TT-3' (product size, 307); IL-17 sense, 5'-TGG AGG CCA TAG TGA AGG-3'; IL-17 antisense, 5'-GGC CAC ATG GTG GAC AAT-3' (product size, 416); -actin sense, 5'-GAG CGG GAA ATC GTG CGT GAC ATT-3'; and -actin antisense, 5'-GAA GGT AGT TTC GTG GAT GCC-3' (product size, 225). Amplification of the PCR products was monitored by measuring SYBR Green I dye fluorescence. The transcript of human -actin, amplified from the same cDNA samples, served as an external standard. Each sample was run in triplicate. Results were analyzed with LightCycler software version 3.5.3 (Roche Diagnostics). The identity of PCR products was confirmed by automated melting curve analysis after the amplification, which revealed the melting temperature (Tm) of the PCR products, followed by gel electrophoresis. In preliminary experiments, PCR products were further analyzed by direct sequencing (ABI PRISM310 Genetic Analyzer; PerkinElmer Applied Biosystems, Norwalk, CT). Quantities of specific mRNA in the sample were measured according to the corresponding gene-specific standard curve. The relative standard curve was prepared with duplicate serial dilutions of cDNA from a sample with the highest predicted levels of expression of the gene being investigated. The standards and the samples were simultaneously amplified using the same reaction master mixture. The results are expressed as fold of induction: (cDNA sample-treated cells/-actin-treated cells)/(cDNA sample untreated cells/-actin untreated cells). The cDNA of untreated control cells normalized to the level of -actin mRNA was ascribed a fold induction of 1. A no-template negative control (H₂O control) was run with every gene-specific primer. The no-RT-PCR control was run with only one primer pair that amplifies a sequence spanning an intron, to rule out contamination with genomic DNA (-actin).

Statistical analysis

Comparison between groups was by Mann-Whitney U test. Paired samples were compared using a Wilcoxon matched pairs signed rank sum test. When appropriate, Bonferroni correction for multiple comparisons was applied.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
RAPBTLs activate cocultured RASFibs, as determined by up-regulated cytokine and adhesion molecule expression

RASFibs constitutively expressed IL-15 on the cell surface, as determined by flow cytometry of nonpermeabilized cells (mean ± SD of positive cells was 9.2 ± 2.3% and MFI was 12.05 ± 1.8). Surface IL-15 expression progressively increased with time upon coculture with RAPBTLs (Fig. 1). At 96 h of coculture, percent positive cells ± SD was 24.4 ± 4.5 (p < 0.05 vs RASFibs alone) (Fig. 1) and MFI was 22.5 ± 2.6 (p < 0.05 vs RASFibs alone); at that time the stimulation index was 1.87 (p < 0.05). Constitutive expression of CD54 (ICAM-1) in resting RASFibs (60 ± 6.2% positive cells, MFI 38.44 ± 3.4) rapidly increased to a plateau at 24 h of coculture (Fig. 1). At 96 h of coculture, percent positive cells ± SD was 97.6 ± 1.2 (p < 0.05 vs RASFibs alone; Fig. 1) and MFI was 156.0 ± 6.5 (p < 0.05 vs RASFibs alone); at that time the stimulation index was 4.1 (p < 0.05).

View larger version (39K): [in this window] [in a new window]   FIGURE 1. Resting RAPBTLs induce an up-regulation of CD54 and surface IL-15 expression in cocultured RASFibs, that is cell contact dependent. For comparison, shown are results using HCPBTLs and RASFTLs. A, Time-course diagrams of surface IL-15 (sIL-15) and CD54 expression on RASFibs cocultured with RAPBTLs, as determined by flow cytometry. Each point represents the arithmetic mean ± SD of 20 subjects per group. B, Representative side scatter-fluorescence dot plots: plots on the left are resting RASFibs stained with anti-IL15 or anti-CD54, middle plots represent RASFibs cocultured for 96 h with PBTLs of a patient with early RA, and on the right, staining with an isotype control mAb is shown. C, Expression of CD54 and surface IL-15 on RASFibs cocultured for 96 h with RAPBTLs, HCPBTLs, or RASFTLs. Cocultures were established allowing contact of RASFibs with TLs (open bars) and also using a 0.4 µM transwell system that separates both cell types into an upper and a lower chamber while sharing cell culture medium (filled bars). Each bar represents the arithmetic mean ± SD of 20 subjects per group. *, p < 0.05 vs resting RASFibs; , p < 0.05 vs RASFibs cocultured with HCPBTLs; ¥, p < 0.05 vs RASFibs cocultured with RAPBTLs (Mann-Whitney U test).

View larger version (25K): [in this window] [in a new window]   FIGURE 2. Resting RAPBTLs induce an up-regulation of IL-15, IL-8, and IL-6 protein and mRNA expression in cocultured RASFibs that is cell contact dependent. For comparison, shown are results using TLs from HCPBTLs and RASFTLs. A, Percent positive cells for intracellular IL-15, IL-8, and IL-6 staining by flow cytometry at 96-h coculture. Cocultures were established, allowing contact of RASFibs with TLs (open bars) and also using a 0.4 µM transwell system that separates both cell types into an upper and a lower chamber while sharing cell culture medium (filled bars). Each bar represents the arithmetic mean ± SD of 20 subjects per group. *, p < 0.05 vs resting RASFibs; , p < 0.05 vs RASFibs cocultured with HCPBTLs; ¥, p < 0.05 vs RASFibs cocultured with RASFTLs (Mann-Whitney U test). B, Representative histograms demonstrate intracellular cytokine staining in RASFibs cocultured with RAPBTLs. Histograms show cytokine expression on resting (gray line) and cocultured (thick black line) RASFibs; the dotted black line represents staining with an isotype control Ab. C, Real-time quantitative analysis of cytokine mRNA expression in RASFibs, at 48-h coculture with TLs. Shown is fold induction referred to expression in RASFibs that were not cocultured with TLs. Results for each cytokine are normalized to -actin expression measured in parallel in each sample. Each bar represents the arithmetic mean ± SD of 20 subjects per group. *, p < 0.05 vs resting RASFibs; , p < 0.05 vs RASFibs cocultured with HCPBTLs; ¥, p < 0.05 vs RASFibs cocultured with RAPBTLs (Mann-Whitney U test).

IL-15 was not detected by ELISA in cell culture supernatants of resting or cocultured cells. In contrast, IL-6 and IL-8 concentrations in supernatants as determined by ELISA paralleled flow cytometry results. Specifically, IL-6 levels in 96-h culture supernatants of RASFibs alone, RASFibs cocultured with HCPBTLs, RASFibs cocultured with RAPBTLs, and RASFibs cocultured with RASFTLs were undetectable, 4.6 ± 0.5, 8.3 ± 0.8, and 15.5 ± 2.1 ng/ml, respectively (mean ± SD). IL-8 levels were undetectable, 3.5 ± 0.4, 7.2 ± 1.1, and 13.4 ± 2.2 ng/ml in culture supernatants of RASFibs alone, RASFibs cocultured with HCPBTLs, RASFibs cocultured with RAPBTLs, and RASFibs cocultured with RASFTLs, respectively.

Cocultures of TLs and synovial fibroblasts separated by 0.4-um inserts did not result in a significant increase of RASFib CD54 or cytokine expression (Figs. 1 and 2). This indicates that direct cell contact is mandatory to initiate cross-talk signals and that the role of soluble mediators released from resting cells is minor.

Resting RASFibs activate cocultured TLs, as determined by increased expression of CD69, CD25, IFN-, TNF-, and IL-17

Because IL-15 shares many properties with IL-2 and has the capacity to activate TLs, we hypothesized that TLs would get stimulated in coculture with RASFibs and looked at TL activation markers and cytokine expression.

CD69 expression was negligible in freshly isolated RAPBTLs (1.9 ± 0.5% positive cells, MFI 1.27 ± 0.4) and markedly increased with time in cocultures with RA SFibs (Fig. 3A); up-regulation was evident at 24 h and further augmented up to 72 h of coculture, reaching a plateau that was maintained up to 120 h (Fig. 3A). At 96 h, 37.3 ± 5.4% cells were CD69 positive (p < 0.05 vs resting RAPBTLs), with a MFI of 85.2 ± 5.4 (p < 0.05 vs resting RAPBTLs) (Fig. 3). CD25 expression was observed in 12.2 ± 1.9% of freshly isolated RAPBTLs with a MFI of 4.5 ± 0.7. An increase of CD25 expression could first be seen in 48-h cocultures and peaked at 96 h (Fig. 3A). At 96 h, 29.3 ± 4.7% cells were CD25 positive (p < 0.05 vs resting RAPBTLs), with a MFI of 17.4 ± 3.1 (p < 0.05 vs resting RAPBTLs) (Fig. 3).

View larger version (23K): [in this window] [in a new window]   FIGURE 3. RASFibs, in a cell contact-dependent manner, up-regulate CD69 and CD25 expression in RAPBTLs. For comparison, shown are results using HCPBTLs and RASFTLs. A, Time-course diagrams of CD69 and CD25 expression on RAPBTLs cocultured with RASFibs, as determined by flow cytometry. Each point represents the arithmetic mean ± SD of 20 subjects per group. B, Representative dot-plots of RAPBTLs, when freshly isolated (left panel) and after 96-h coculture with RASFibs (right panel). C, Expression of CD69 and CD25 on RAPBTLs, HCPBTLs, or RASFTL, cocultured with RASFibs for 96 h. Cocultures were established allowing contact of RASFibs with TLs (open bars) and also using a 0.4 µM transwell system that separates both cell types into an upper and a lower chamber (filled bars). Each bar represents the arithmetic mean ± SD of 20 subjects per group. *, p < 0.05 vs same population resting TLs; , p < 0.05 vs cocultured HCPBTLs; ¥, p < 0.05 vs cocultured RAPBTLs (Mann-Whitney U test).

RAPBTLs did not constitutively synthesize IFN- (0.08% ± 0.003 positive cells; MFI 0.02 ± 0.001), TNF- (0.07 ± 0.002% positive cells; MFI 0.02 ± 0.001), or IL-17 protein (0.13 ± 0.03 positive cells; MFI 0.05 ± 0.002), as determined by intracellular staining and flow cytometry. In cocultures with RASFibs, intracellular IFN-, TNF-, and IL-17 could be seen at 24 h, increased at 48 h, and peaked at 96 h, reaching a plateau that was maintained up to 120 h of coculture. At 96 h of coculture, intracellular TNF- expression by flow cytometry (% positive cells ± SD) was 32.5 ± 5.3 (p < 0.05 vs resting RAPBTLs) with a MFI of 40.5 ± 3.8 (p < 0.05 vs resting RAPBTLs), IFN- expression was 27.3 ± 4.1% cells (p < 0.05 vs resting RAPBTLs) with a MFI of 17.36 ± 1.9 (p < 0.05 vs resting RAPBTLs), and IL-17 expression was 38 ± 5.2% cells (p < 0.05 vs resting RAPBTLs) with a MFI of 18.09 ± 2.5 (p < 0.05 vs resting RAPBTLs) (Fig. 4).

View larger version (25K): [in this window] [in a new window]   FIGURE 4. RASFibs induce TNF-, IFN-, and IL-17 protein and mRNA expression in cocultured freshly isolated RAPBTLs. This effect is cell contact dependent. For comparison, shown are results using HCPBTLs and RASFTLs. A, TL cytokine expression at 96-h coculture with RASFibs, as determined by intracellular staining and flow cytometry. Cocultures were established allowing contact of RASFibs with TLs (open bars) and also using a 0.4 µM transwell system that separates both cell types into an upper and a lower chamber (filled bars). Each bar represents the arithmetic mean ± SD of 20 subjects per group. *, p < 0.05 vs same population resting TLs; , p < 0.05 vs cocultured HCPBTLs; ¥, p < 0.05 vs cocultured RAPBTLs (Mann-Whitney U test). B, Representative histograms demonstrate intracellular cytokine staining in RAPBTLs, cocultured with RASFibs for 96 h. Histograms show cytokine expression on resting (gray line) and cocultured (thick black line) TLs; the dotted black line represents staining with an isotype control Ab. C, Real-time quantitative analysis of cytokine mRNA expression in TLs, at 48-h coculture with RASFibs. Shown is fold induction referred to expression in resting TLs. Results for each cytokine are normalized to -actin expression measured in parallel in each sample. Each bar represents the arithmetic mean ± SD of 20 subjects per group. *, p < 0.05 vs same population resting TLs; , p < 0.05 vs cocultured HCPBTLs; ¥, p < 0.05 vs cocultured RAPBTLs (Mann-Whitney U test).

TNF- levels in 96-h culture supernatants of RASFibs alone, RASFibs cocultured with HCPBTLs, RASFibs cocultured with RAPBTLs, and RASFibs cocultured with RASFTLs were undetectable, 240 ± 20, 502 ± 53, and 1215 ± 152 pg/ml, respectively (mean ± SD). IFN- levels were undetectable, 180 ± 28, 386 ± 45, and 875 ± 92 pg/ml in culture supernatants of RASFibs alone, RASFibs cocultured with HCPBTLs, RASFibs cocultured with RAPBTLs, and RASFibs cocultured with RASFTLs, respectively. IL-17 levels were undetectable, 120 ± 18, 338 ± 42, and 932 ± 220 pg/ml.

Real-time RT-PCR revealed an increased expression of TNF-, IFN- and IL-17 mRNA in TLs cocultured with RASFibs (Fig. 4C).

Cocultures of TLs and synovial fibroblasts separated by 0.4-µm inserts did not result in a significant increase of TL activation marker or cytokine expression, suggesting that the role of soluble mediators released from resting cells is minor.

TL expression of ICAM-1 and LFA-1 was not modified in cocultures. CD40L and CTLA-4 were not expressed on resting TLs and were not induced up to 120 h after initiating cocultures.

Role of IL-15 and CD54 on activation of TLs cocultured with RASFibs

We next sought to establish whether IL-15 expressed by RASFibs is implicated in activation of cocultured T lymphocytes. Up-regulation of CD69, CD25, IFN-, TNF-, and IL-17 in TLs cocultured with RASFibs were significantly inhibited by a blocking anti-IL-15 mAb, by a blocking polyclonal goat IgG anti-IL-15R, and by a recombinant IL-15R/Fc chimera, but not by an irrelevant, isotype-matched mAb, not by normal goat IgG, and not by normal human IgG (Fig. 5A). A blocking anti-IL2-IL15-R mAb was moderately effective at down-regulating TL activation (Fig. 5A). These data suggest that IL-15 plays a major role in cell contact-mediated activation of TLs by RASFibs.

View larger version (36K): [in this window] [in a new window]   FIGURE 5. Molecules implicated in TL/RASFib cross-talk. RASFibs were cocultured with RAPBTLs in the presence of specific neutralizing Abs. Surface or intracellular staining and flow cytometry was done in 96-h cocultures. Percentage inhibition by neutralizing Abs is shown, referred to cytokine or surface molecule expression in cocultures without neutralizing Abs. Percent inhibition was calculated as follows: 100 – [(cytokine/surface marker expression with neutralizing Ab present)/(cytokine/surface marker expression without neutralizing Ab present)] x 100. A, Activation of RAPBTLs induced by cocultured RASFibs is markedly decreased in the presence of a neutralizing anti-IL-15 mAb, a neutralizing goat polyclonal anti-IL-15R, a chimeric IL-15R-Fc construct, and a neutralizing anti-IL2R mAb, but not when a nonspecific isotype control mAb, goat IgG, or human IgG is added to the culture. B, Activation of RAPBTLs induced by cocultured RASFibs is markedly decreased in the presence of blocking mAbs to IL-15 or CD54, but not when an anti-HLA class I or an irrelevant, isotype control mAb is added to the cultures. C, RASFib activation induced by RAPBTLs is markedly decreased when using mAbs to CD69, LFA-1 (CD11a), TNF-, IFN-, or IL-17, but not an isotype control mAb. Each bar represents the arithmetic mean ± SD of 20 subjects per group, except for experiments using anti-IL15R, IL15RFc, and anti-IL2R, in which only 12 subjects per group were tested. *, p < 0.01 vs isotype control or normal IgG.

Role of TL surface molecules and cytokines on activation of RASFibs

A blocking mAb to LFA-1 (CD11a) significantly decreased percent TL-induced activation of RASFibs, thereby confirming the importance of the CD54/LFA-1 adhesion pathway in this system (Fig. 5C). An Ab directed to CD69 was efficient at abrogating percent TL-induced up-regulation of RASFib cytokines and CD54 (Fig. 5C). TL cytokines that were induced in cocultures importantly contribute to activating RASFibs, as suggested by inhibition of RASFib stimulation when using mAbs to IL-17, TNF-, or IFN- (Fig. 5C).

Resting OASFibs and dermal fibroblasts do not express surface IL-15: behavior of OASFibs and dermal fibroblasts in coculture with TLs

We were then interested in determining whether OASFibs and dermal fibroblasts constitutively express surface IL-15. As shown in Fig. 6A, no surface IL-15 expression could be detected on resting OASFibs or on dermal fibroblasts. In contrast, both OASFibs and dermal fibroblasts constitutively expressed intracellular IL-15 (Fig. 6A). Interestingly, intracellular IL-15 expression was significantly lower in resting OASFibs and dermal fibroblasts when compared with RASFibs (Fig. 6A).

View larger version (21K): [in this window] [in a new window]   FIGURE 6. Comparison of RASFib, OASFib, and dermal fibroblast behavior in 96-h coculture with TLs. A, Surface and intracellular IL-15 expression in RASFibs, OASFibs, and dermal fibroblasts, under resting conditions and at 96 h. coculture with HCPBTL, RAPBTL or RASFTL. * p < 0.005 vs RASFib; p < 0.05 vs resting fibroblasts of same tissue origin. Each bar represents the arithmetic mean ± SD of 20 subjects per group (coculture with RASFibs) or 10 subjects per group (cocultures with OASFibs and dermal fibroblasts). B, Expression of CD69 and intracellular IL-17 in HCPBTLs, RAPBTLs, and RASFTLs, under resting conditions and in coculture with RASFibs, OASFibs, or dermal fibroblasts. *, p < 0.05 vs TLs cocultured with RASFibs; , p < 0.005 vs resting TLs of same origin. Each bar represents the arithmetic mean ± SD of 20 subjects per group (coculture with RASFibs) or 10 subjects per group (cocultures with OASFibs and dermal fibroblasts). C, Expression of CD69 and intracellular IL-17 in RAPBTLs cocultured with PFA-fixed RASFibs, OASFibs, or dermal fibroblasts. Cells were cocultured in medium alone, with a neutralizing anti-IL-15 mAb, or with an isotype control mAb. *, p < 0.01 vs resting RAPBTLs. Each bar represents the arithmetic mean ± SD of 10 subjects per group.

To evaluate the role of surface IL-15 on the differential behavior of RASFibs when compared with OASFibs and dermal fibroblasts, resting fibroblast cultures were fixed with PFA and then cocultured with RAPBTLs. PFA fixation of cells is known to prevent cytokine production while preserving cell membrane integrity, and this provides a simple experimental system for investigating cell contact-mediated effects (33). In our system, PFA-fixed SFibs did not secrete cytokines even when fixed after stimulation with IL-1 (1 ng/ml).

As seen in Fig. 6C, PFA-fixed RASFibs, but not OASFibs or dermal fibroblasts, were able to induce an up-regulation of CD69 and IL-17 expression in cocultured RAPBTLs, although at lower levels than those seen with living RASFibs. This effect was abrogated by a neutralizing anti-IL-15 mAb but not by an isotype control mAb.

T cell subsets involved in interactions with RASFibs

We next examined whether the observed interactions are T cell subset-specific. To determine which subsets of T lymphocytes actively interact with RASFibs, CD4⁺, CD8⁺, CD45RO⁺, and CD45RA⁺ cells were magnetically isolated from peripheral blood of five early RA patients, and these subsets were tested in coculture experiments. Although no significant differences where observed between CD4⁺ and CD8⁺ subsets, CD45RO T cells demonstrated a higher capacity to stimulate and be stimulated by RASFibs when compared with CD45RA TLs (Fig. 7). Observed differences persisted when applying Bonferroni correction for multiple comparisons.

View larger version (60K): [in this window] [in a new window]   FIGURE 7. T cell subsets involved in interactions with RASFibs. CD4+, CD8+, CD45RO+, and CD45RA+ subsets were magnetically sorted from PBMCs of five patients with early RA, and cocultures with RASFibs were established. Surface molecule and cytokine expression in RASFibs and TLs were determined by flow cytometry at 96-h coculture. Also shown are results of coculture experiments with T cells of seven early RA patients whose HLA-DR expression was above the maximum observed in HCPBTLs ("HLA-DR" T cells) and 13 RA patients whose HLA-DR expression was below the maximum observed in HCPBTLs ("HLA-DR–" T cells). A, Cytokine and CD54 induction or up-regulation in RASFibs cocultured with unfractionated, CD4, CD8, CD45RO, or CD45RA T cells and with HLA-DR or HLA-DR– T cells. B, Induction or up-regulation of CD69, CD25, intracellular TNF-, intracellular IFN-, and intracellular IL-17 in unfractionated, CD4, CD8, CD45RO, and CD45RA T cells and in HLA-DR or HLA-DR– T cells, cocultured with RASFibs. Each bar represents the arithmetic mean ± SD of 5 subjects with early RA (magnetical separation studies), 7 early RA patients with increased HLA-DR expression, or 13 early RA patients with HLA expression within normal limits. *, p < 0.05 vs CD45RO subset after Bonferroni correction for multiple comparisons.

Excluding an allogeneic effect

Previous work of others has demonstrated that no allogeneic effects are observed in cocultures of human fibroblasts with allogeneic T cells (8, 34). Nevertheless, it was important to exclude subtle allogeneic effects in our system. To this end, RASFibs were cocultured with autologous or allogeneic RAPBTLs within a single experiment (Fig. 8). Results from three such experiments showed comparable percent activation when autologous or allogeneic T lymphocytes were cocultured with RASFibs (Fig. 8).

View larger version (36K): [in this window] [in a new window]   FIGURE 8. Comparison of cocultures using autologous and heterologous RAPBTLs and RASFibs. Two RASFib cell lines were cocultured with autologous RAPBTLs and also with heterologous RAPBTLs from two different donors. Surface molecules and intracellular cytokines were determined by flow cytometry at 96-h coculture. A, Cytokine expression in two different RASFib lines cocultured with autologous or heterologous RAPBTLs from two different donors. Up-regulation of surface IL-15 (s-IL15) and induction of intracellular IL-8 (i-IL8) expression were comparable in autologous and heterologous cocultures. B, Expression of CD69 and intracellular IL-17 in RAPBTLs of two different patients cocultured with autologous or heterologous RASFibs. Representative of three different experiments on three separate days with different RASFib lines and blood donors.

Because MTX is still the most commonly used drug in RA and because most of our patients require MTX as a disease modifying drug immediately after diagnosis is confirmed, the in vitro effect of MTX on RASFib/TL interactions was tested. A dose-dependent inhibition of RASFib/TL cross-talk signals was observed. As an example, shown are dose-response curves of RASFib surface IL-15 and of RAPBTL CD69 expression in 96-h cocultures (Fig. 9, A and B). Low-percentage inhibition was already seen with MTX 1 nM, and the effect was maximal with MTX 100 nM (Fig. 9, A and B).

View larger version (18K): [in this window] [in a new window]   FIGURE 9. Methotrexate down-regulates bidirectional RASFib/TL activation. RASFibs were pretreated with MTX (10–500 nM) 4 h before starting cocultures. Subsequently, RAPBTLs were added to the culture, without washing away MTX. Surface or intracellular staining and flow cytometry was done at 96-h coculture. Percentage inhibition by MTX is shown, referred to cytokine or surface molecule expression in cocultures without MTX. Percent inhibition was calculated as follows: 100 – [(cytokine/surface marker expression with MTX present)/(cytokine/surface marker expression without MTX present)] x 100. A and B, MTX inhibits coculture-induced up-regulation of surface IL-15 on RASFibs and of CD69 on RAPBTLs, in a dose-dependent manner. This effect is reversed by ADA (0.125 IU/ml) and by the adenosine A2 receptor antagonist DMPX (10 µM). C and D, MTX (100 nM) inhibits up-regulation of RASFib (C) and RAPBTL (D) surface molecule and intracellular cytokine expression. Inhibition is reversed by ADA and by DMPX. E, MTX decreases adhesion of TLs to RASFibs in a dose-dependent manner; the effect is reversed by ADA and by DMPX. Each bar represents the mean ± SD of 20 patients. *, p < 0.01 vs expression in conditions without MTX present.

Because MTX has been described to decrease adhesion of neutrophils to endothelium and to dermal fibroblasts (35), we sought to determine whether it interferes with adhesion of TLs to RASFibs. The number of RAPBTLs that were firmly adhered to fibroblasts was counted in MTX-treated and untreated 96-h cocultures. Interestingly, a marked decrease in the number of adherent lymphocytes was seen in the MTX-treated wells (Fig. 9E), suggesting that the effect of MTX on RASFib/TL cross-talk signals may be mediated, at least in part, by decreased cell adhesion. The effect of MTX on adhesion was dose-dependent: it was reversed by ADA (0.125 IU/ml) and by DMPX (10 µm) (Fig. 9E), but not by DPCPX (data not shown).

In vivo effect of treatment

We also sought to determine whether disease control with treatment results in decreased TL-RASFib cross-talk signals. Five patients with early RA donated blood for a second time, once disease activity had been controlled. Blood was also obtained from the five healthy subjects who had previously acted as controls for these patients. As seen in Fig. 10, bidirectional activation in RASFib/RAPBTL cocultures was significantly decreased when compared with responses before initiation of treatment. Experimental variation observed in healthy controls was minimal. These results indicate that the basal activated state displayed by PBTLs of early RA patients is down-regulated in vivo by disease-modifying agents while controlling disease activity.

View larger version (20K): [in this window] [in a new window]   FIGURE 10. Control of disease with treatment results in down-regulation of TL/RASFib cross-talk signals. PBTLs were isolated for a second time from five patients with early RA, once disease control had been achieved with oral MTX plus low-dose prednisone. Blood was also obtained from the five healthy subjects who had previously served as controls for these patients. Cocultures with RASFibs were established (RASFibs were the same fibroblast lines used for experiments before treatment). Expression of cytokines, adhesion molecules, and activation markers in TLs and RASFibs was determined by flow cytometry in 96-h cocultures. Results were compared for each patient with results obtained before initiation of treatment. Percent inhibition was calculated as follows for each patient: 100 – [(cytokine/surface marker expression before starting oral MTX)/(cytokine/surface marker expression at disease control with MTX)] x 100. For healthy controls, percent variation was calculated as follows: 100 – [(cytokine/surface marker expression at initial experiment)/(cytokine/surface marker expression at "disease control" experiment)] x 100. Each bar represents the mean ± SD of five subjects. *, p < 0.01 vs expression before starting MTX.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

When compared with PBTLs of healthy controls, PBTLs from early RA patients were more efficient at inducing activation of RASFibs and also were more easily activated in cocultures, indicating the existence of a previously activated state favoring cell contact-mediated responses. However, expression of CD25, CD69, and CD40L was not elevated in RAPBTLs, and expression of HLA-DR was only slightly increased when compared with HCPBTLs. Further studies are needed to elucidate the mechanisms underlying the functional behavior of RAPBTLs in coculture with RASFibs. Functional differences between peripheral blood T cells of RA and healthy controls have previously been described, and the mechanisms responsible for these differences are largely unknown (37). In our system, the observed preactivated state was no longer present in PBTLs of early RA patients once disease activity was controlled with treatment (MTX + low-dose prednisone). Freshly isolated TLs from RA synovial fluid, with increased basal CD69 and CD25 expression, were more efficient at RASFib activation when compared with TLs from peripheral blood of early RA. This confirms the in vivo relevance of the pathways detected in vitro.

Experiments with transwell inserts suggest that direct cell contact is mandatory to initiate RASFib-TL cross-talk. Once intercellular cross-talk is initiated by direct contact, soluble factors such as IL-17, IL-6, and IL-8 are liberated, which contribute to augmenting the proinflammatory loop.

The observed effects are not attributable to an allogeneic reaction because a blocking anti-MHC class I mAb did not display any significant effect. In addition, comparable percent activation was observed in autologous and allogeneic RASFib/RAPBTL cocultures. Previous work of others has shown that cocultures of fibroblasts and T lymphocytes from different donors do not result in allogeneic reactions, and this is attributable to poor or absent fibroblast expression of costimulatory molecules CD80 and CD86 (8, 38). In fact, Corrigall et al. (38) reported that lack of CD80 and CD86 on synovial fibroblasts results in T cell anergy with no response to allogeneic stimulation and a conserved response to recombinant human IL-2.

Our initial hypothesis stated that surface IL-15 is key to contact-dependent activation of TL. This was confirmed in experiments with neutralizing Abs to IL-15, IL-15R, and IL-R and with a soluble IL15R-Fc chimera. IL-17, IFN-, and TNF- expression in cocultured TLs were significantly decreased by blockade of IL-15 and IL-15R components, suggesting that IL-15 plays a major role in TL cytokine induction (Fig. 11). Likewise, increased CD69 and CD25 expression were IL-15 dependent (Fig. 11).

View larger version (42K): [in this window] [in a new window]   FIGURE 11. Fibroblast IL-15 stimulates T cells through direct cell contact. A, RASFibs constitutively express surface IL-15. Most cell surface IL-15 seems to be attached to IL-15R. This mechanism is favored by the high affinity of IL-15R, which rapidly takes up secreted IL-15. Alternatively, surface IL-15 may be directly anchored to the plasma membrane through a signal peptide or GPI or indirectly bound to as yet unknown receptors (these three alternative mechanisms have beeen depicted as "X"). B, IL-15 bound to IL-15R on the surface of RASFib is able to stimulate neighboring T cells in trans, through IL-2R and common -chains. In addition, secreted IL-15 and IL-15 anchored to plasma membrane may stimulate adherent T cells in cis by binding T cell IL-15R. T cell IL-15R would compete with fibroblast IL-15R for secreted IL-15. C, Fibroblast IL-15 up-regulates T cell CD69, CD25, IL-17, TNF-, and IFN- expression that contribute to further increasing IL-15 and induce fibroblast IL-6 and IL-8 secretion. This constitutes a feedback loop that perpetuates the inflammatory process.

The secretion of IL-15 is very exquisitely regulated and not yet well understood (39). IL-15R has a very high affinity for IL-15 (K_d = 10 pM) compared with the low affinity of IL-2R for IL-2 (K_d = 10 nM) (39). It has been proposed that the high affinity of IL-15R results in an extremely rapid uptake of secreted IL-15 by producer cells and also by neighboring cells, thereby preventing detection of IL-15 in culture supernatants (40, 41) (Fig. 11). This mechanism implies autocrine as well as paracrine activation and has been termed "intercellular recirculation of IL-15" (40). Furthermore, Dubois et al. (41) demonstrated that most of the IL-15 detected on cell surfaces is bound to IL-15R (Fig. 11) and that the complex IL15/IL-15R is biologically active on neighboring cells through direct cell contact (41): in fact, IL-15R is able to present IL-15 in trans to cells expressing the IL-15R and IL-15R chains (41) (Fig. 11). Surface, IL-15R-bound IL-15 has a wider biological activity than does soluble IL-15 because the signal induced in trans by the IL-15/IL-15R complex can stimulate efficiently at picomolar concentrations the proliferation of both - and IL-15R--bearing cells in a similar manner (41). That is, the presence of surface IL-15R-bound IL-15 is synonymous with active IL-15 secretion (Fig. 11), and the level of expression of surface IL-15 in a fibroblast cell population may reflect the rate of internalization of the IL-15/IL-15R complex. It has been proposed that IL-15 may also interact with the plasma membrane independent of its receptor (Fig. 11). Potentially, this could occur indirectly through interactions with as yet unidentified receptors or directly through either one of the IL-15 abnormal N terminus signaling peptides or by the addition of a predicted C terminus GPI anchor (42). In summary, IL-15 is not usually secreted to the extracellular space in a soluble form but remains attached to the plasma membrane; therefore direct cell contact is necessary for the action of IL-15 to take place (Fig. 11).

Blocking anti-CD54 Abs demonstrated that ICAM-1 (CD54) is also implicated in activation of TLs, consistent with previous reports on the effect of the LFA-1/ICAM-1 adhesion pathway in the activation of peripheral blood TLs (43) and leukocytes (44). It remains to be determined whether the effect of CD54 is exclusively related to adhesion or whether CD54 has an intrinsic activating effect (45, 46). Simultaneous blockade of IL-15 and CD54 was synergistic at decreasing TL-RASFib cross-talk. Blocking mAbs to CD11a likewise decreased RASFib activation induced by cocultured TLs, thereby suggesting a role for ₂ integrins in this coculture system and stressing the importance of cell adhesion in RATL-SFib cross-talk.

The TL surface marker CD69 is important in contact-dependent RASFib activation, because a mAb to CD69 moderately decreased the up-regulated RASFib expression of IL-15, IL-6, IL-8, and CD54 induced by cocultured TLs. CD69 has been implicated in contact-mediated TL activation in previous in vitro studies (23, 47). In contrast, recent work (48) with CD69 knockout mice suggests that CD69 may have an anti-inflammatory role mediated by increased production of TGF-, leading to decreased proinflammatory cytokine production. Further studies are needed to clarify discrepancies in the putative function of CD69 derived from in vitro studies as opposed to in vivo animal models.

The induction of IL-17 in cocultures is an important contributor to the feedback loop. A blocking mAb to IL-17 significantly decreased contact-dependent RASFib IL-6 and IL-8 expression and had a moderate inhibitory effect on up-regulation of CD54 and IL-15. TL-derived TNF- and IFN- are also important players, because RASFib activation was down-regulated by specific blocking mAbs. IL-17 is a novel cytokine produced by activated T cells (49, 50), and elevated levels of IL-17 have been described in synovial fluids of RA but not OA patients (49, 50). In addition, CD4CD45RO T cells in synovial tissue of RA patients are immunoreactive with anti-IL-17 Abs (50), and cultured pieces of RA synovium produce IL-17 (51). This, together with the findings in our coculture system, suggests that blocking the action of IL-17 may help control disease activity in RA.

In an excellent previous study, Yamamura et al. (8) reported that TLs from healthy donors and RA patients do not show any sign of activation when cocultured with RASFibs; however, RASFibs were stimulated upon contact with T cells, as determined by induction of IL-6, IL-8, and PGE₂ production (8). This contrasts with our findings and with recent evidence that PBTLs proliferate when cocultured with RA synovial fibroblasts (12). We can only speculate that factors such as lower coculture time frame in Yamamura’s system, previous treatment of patients, and/or a higher T cell:RASFib ratio may explain differences.

MTX attenuated the RAPBTL activation induced by RASFibs in vitro and it also modulated the up-regulation of RASFib IL-15, IL-6, and IL-8 induced by RAPBTLs. At the same time, MTX significantly decreased RAPBTL adhesion to RASFibs. Because cell contact is important for the bidirectional SFib/TL cross-talk, decreased SFib/TL adhesion could be one mediator of MTX effect in this coculture system. MTX is the most commonly used drug in RA and its mechanism of action is still being investigated (52). At the low doses used for RA treatment, MTX induces release of adenosine to the extracellular space (52). Adenosine is a potent anti-inflammatory autacoid and mediates MTX inhibition of neutrophil adhesion to endothelium and fibroblasts (52). In our system, the effect of MTX was reversed by ADA and by the adenosine A2 receptor antagonist DMPX. This suggests that adenosine release plays a role in the observed effects acting through A2 receptors, similar to the effect of adenosine on neutrophil adhesion to endothelial cells (53). MTX did not modify the expression of CD54 or CD11a in resting or cocultured cells. This may indicate that MTX effect on adhesion is mediated by changes in the affinity and/or avidity of adhesion molecules, consistent with previous reports that LFA-1 function can be modulated without changing cell surface expression levels (54). Our experiments with PBTLs of early RA patients who subsequently received oral MTX showed that MTX, while controlling disease activity, modifies the capacity of peripheral blood T cells to activate and be activated by RASFibs. Previous reports have demonstrated in vivo effects of MTX in animal models, such as decreased recruitment of TLs to the arthritic joint of mice with collagen-induced arthritis (55). Clinical improvement with MTX in rheumatoid synovitis has been associated with a significant decrease in the number of T cells infiltrating the synovial membrane (56, 57) and also with decreased migration and articular recruitment of neutrophils (58).

In summary, constitutively expressed IL-15 on RA synovial fibroblasts is able to stimulate freshly isolated T cells. This generates a positive feedback loop whereby IL-15 induces and maintains T cell synthesis of TNF-, IFN-, and IL-17, which can further activate RASFibs to produce IL-15 and also IL-6 and IL-8 (Fig. 11). TLs from early RA patients particularly contribute to this effect, showing increased responses when compared with healthy controls. This implies that circulating T cells from RA patients may participate in the initiation and perpetuation of the RA joint inflammation. The T cell/synovial fibroblast cross-talk loop could favor residual inflammation in RA patients who fail to respond to TNF- treatment. MTX, still the most commonly used drug in RA, interferes with RASFib/TL cross-talk by decreasing heterotypic adhesion.

	Footnotes

 
¹ This work was supported by Ministerio de Ciencia y Tecnología Programa Ramón y Cajal (to M.-E.M.-C.), Ministerio de Ciencia y Tecnología Grant SAF 2002-03360 (to M.-E.M.-C.), and a Hospital La Paz Research Grant (to M.B.-M.).

² Address correspondence and reprint requests to Dr. María-Eugenia Miranda-Carús, Department of Rheumatology, Hospital La Paz, Paseo de la Castellana, 261, 28046 Madrid, Spain. E-mail address: eugeniamiranda{at}telefonica.net

³ Abbreviations used in this paper: RA, rheumatoid arthritis; RASFib, RA synovial fibroblast; TL, T lymphocyte; SFib, synovial fibroblast; OA, osteoarthritis; MTX, methotrexate; DAS28, disease activity score 28; RAPBTL, peripheral blood TL from early RA patient; HCPBTL, peripheral blood TL from healthy control; RASFTL, synovial fluid TL from RA patient; PFA, paraformaldehyde; ADA, adenosine deaminase; DMPX, 3,7-dimethyl-1-propargylxanthine; DPCPX, 8-cyclopentyl-dipropylxanthine; MFI, mean fluorescence intensity.

Received for publication February 5, 2004. Accepted for publication May 13, 2004.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Firestein, G. S.. 1996. Invasive fibroblast-like synoviocytes in rheumatoid arthritis: passive responders or transformed aggressors?. Arthritis Rheum. 39:1781.[Medline]
2. Fox, D. A.. 1997. The role of T cells in the immunopathogenesis of rheumatoid arthritis: a new perspective. Arthritis Rheum. 40:598.[Medline]
3. Aarvak, T., J. B. Natvig. 2001. Cell-cell interactions in synovitis: antigen presenting cells and T cell interaction in rheumatoid arthritis. Arthritis Res. 3:13.[Medline]
4. McInnes, I. B., B. P. Leung, F. Y. Liew. 2000. Cell-cell interactions in synovitis: interactions between T lymphocytes and synovial cells. Arthritis Res. 2:374.[Medline]
5. Postlethwaite, A. E.. 1995. Role of T cells and cytokines in effecting fibrosis. Int. Rev. Immunol. 12:247.[Medline]
6. Rezzonico, R., D. Burger, J. M. Dayer. 1998. Direct contact between T lymphocytes and human dermal fibroblasts or synoviocytes down-regulates types I and III collagen production via cell-associated cytokines. J. Biol. Chem. 273:18720.[Abstract/Free Full Text]
7. Murakami, S., E. Hino, Y. Shimabukuro, T. Nozaki, Y. Kusumoto, T. Saho, F. Hirano, H. Hirano, H. Okada. 1999. Direct interaction between gingival fibroblasts and lymphoid cells induces inflammatory cytokine mRNA expression in gingival fibroblasts. J. Dent. Res. 78:69.[Abstract/Free Full Text]
8. Yamamura, Y., R. Gupta, Y. Morita, X. He, R. Pai, J. Endres, A. Freiberg, K. Chung, D. A. Fox. 2001. Effector function of resting T cells: activation of synovial fibroblasts. J. Immunol. 166:2270.[Abstract/Free Full Text]
9. Buckley, C. D., D. Pilling, J. M. Lord, A. N. Akbar, D. Scheel-Toeller, M. Salmon. 2001. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol. 22:199.[Medline]
10. Scott, S., F. Pandolfi, J. T. Kurnick. 1990. Fibroblasts mediate T cell survival: a proposed mechanism for retention of primed T cells. J. Exp. Med. 172:1873.[Abstract/Free Full Text]
11. Salmon, M., D. Scheel Toellner, A. P. Huissoon, D. Pilling, N. Shamsadeen, H. Hyde, A. D. D’Angeac, P. A. Bacon, P. Emery, A. N. Akbar. 1997. Inhibition of T cell apoptosis in the rheumatoid synovium. J. Clin. Invest. 99:439.[Medline]
12. Vallejo, A. N., H. Yang, P. A. Klimiuk, C. M. Weyand, J. J. Goronzy. 2003. Synoviocyte-mediated expansion of inflammatory T cells in rheumatoid synovitis is dependent on CD47-thrombospondin 1 interaction. J. Immunol. 171:1732.[Abstract/Free Full Text]
13. McInnes, I. B., F. Y. Liew. 1998. Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis. Immunol. Today 19:75.[Medline]
14. Kurowska, M., W. Rudnicka, E. Kontny, I. Janicka, M. Chorazy, J. Kowalczewski, M. Ziolkowska, S. Ferrari-Lacraz, T. B. Strom, W. Maslinski. 2002. Fibroblast-like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bcl-x_L and Bcl-2. J. Immunol. 169:1760.[Abstract/Free Full Text]
15. Grabstein, K. H., J. Eisenman, K. Shanebeck, C. Rauch, S. Srinivasan, V. Fung, C. Beers, J. Richardson, M. A. Schoenborn, M. Ahdieh, et al 1994. Cloning of a T cell growth factor that interacts with the -chain of the interleukin-2 receptor. Science 264:965.[Abstract/Free Full Text]
16. Giri, J. G., M. Ahdieh, J. Eisenman, K. Shanebeck, K. Grabstein, S. Kumaki, A. Namen, L. S. Park, D. Cosman, D. Anderson. 1994. Utilization of the - and ’67-chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 13:2822.[Medline]
17. Lodolce, J. P., P. R. Burkett, D. L. Boone, M. Chien, A. Ma. 2001. T cell-independent interleukin receptor- signals are required for bystander proliferation. J. Exp. Med. 194:1187.[Abstract/Free Full Text]
18. Liu, K., M. Catalfamo, Y. Li, P. A. Henkart, N. P. Weng. 2002. IL-15 mimics T cell receptor crosslinking in the induction of cellular proliferation, gene expression, and cytotoxicity in CD8⁺ memory T cells. Proc. Natl. Acad. Sci. USA 99:6192.[Abstract/Free Full Text]
19. Briard, D., D. Brouty-Boye, B. Azzarone, C. Jasmin. 2002. Fibroblasts from human spleen regulate NK cell differentiation from blood CD34⁺ progenitors via cell surface IL-15. J. Immunol. 168:4326.[Abstract/Free Full Text]
20. Rappl, G., A. Kapsokefalou, C. Heuser, M. Rossler, S. Ugurel, W. Tilgen, U. Reinhold, H. Abken. 2001. Dermal fibroblasts sustain proliferation of activated T cells via membrane-bound interleukin-15 upon long-term stimulation with tumor necrosis factor-. J. Invest. Dermatol. 116:102.[Medline]
21. McInnes, I. B., J. al-Mughales, M. Field, B. P. Leung, F. P. Huang, R. Dixon, R. D. Sturrock, P. C. Wilkinson, F. Y. Liew. 1996. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat. Med. 2:175.[Medline]
22. Gonzalez-Alvaro, I., A. M. Ortiz, R. Garcia-Vicuna, A. Balsa, D. Pascual-Salcedo, A. Laffon. 2003. Increased serum levels of interleukin-15 in rheumatoid arthritis with long-term disease. Clin. Exp. Rheumatol. 21:639.[Medline]
23. McInnes, I. B., B. P. Leung, R. D. Sturrock, M. Field, F. Y. Liew. 1997. Interleukin-15 mediates T-cell dependent regulation of tumor necrosis factor- production in rheumatoid arthritis. Nat. Med. 3:189.[Medline]
24. Ruchatz, H., B. P. Leung, X. Wei, I. B. McInnes, F. Y. Liew. 1998. Soluble IL-15 receptor-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. J. Immunol. 160:5654.[Abstract/Free Full Text]
25. McInnes, I. B., J. A. Gracie, M. Harnett, W. Harnett, F. Y. Liew. 2003. New strategies to control inflammatory synovitis: interleukin 15 and beyond. Ann. Rheum. Dis. 62:(Suppl. 2):ii51.[Free Full Text]
26. Arnett, F. C., S. M. Edworthy, D. A. Bloch, D. J. McShane, J. F. Fries, N. S. Cooper, L. A. Healey, S. R. Kaplan, M. H. Liang, H. S. Luthra, et al 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:315.[Medline]
27. van der Heijde, D. M., M. A. van’t Hof, P. L. van Riel, L. A. Theunisse, E. W. Lubberts, M. A. van Leeuwen, M. H. van Rijswijk, L. B. van de Putte. 1990. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann. Rheum. Dis. 49:916.[Abstract/Free Full Text]
28. Saalbach, A., U. F. Haustein, U. Anderegg. 2000. A ligand of human thy-1 is localized on polymorphonuclear leukocytes and monocytes and mediates the binding to activated thy-1-positive microvascular endothelial cells and fibroblasts. J. Invest. Dermatol. 115:882.[Medline]
29. Dhawan, J., A. C. Lichtler, D. W. Rowe, S. R. Farmer. 1991. Cell adhesion regulates pro-1(I) collagen mRNA stability and transcription in mouse fibroblasts. J. Biol. Chem. 266:8470.[Abstract/Free Full Text]
30. Majors, A. K., L. A. Ehrhart. 1992. Cell density and proliferation modulate collagen synthesis and procollagen mRNA levels in arterial smooth muscle cells. Exp. Cell Res. 200:168.[Medline]
31. Gadangi, P., M. Longaker, D. Naime, R. I. Levin, P. Recht, M. C. Montesinos, M. T. Buckley, G. Carlin, B. N. Cronstein. 1996. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J. Immunol. 156:1937.[Abstract]
32. Balsa, A., L. Carmona, I. Gonzalez-Alvaro, M. A. Belmonte, X. Tena, R. Sanmarti, EMECAR Study Group. 2004. Value of disease activity score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. J. Rheumatol. 31:40.[Abstract/Free Full Text]
33. Lacraz, S., P. Isler, E. Vey, H. G. Welgus, J. M. Dayer. 1994. Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. J. Biol. Chem. 269:22027.[Abstract/Free Full Text]
34. Tsai, C., Jr., L. A. Diaz, N. Singer, L. L. Li, A. H. Kirsch, R. Mitra, B. Nickoloff, L. J. Crofford, D. A. Fox. 1996. Responsiveness of human T lymphocytes to bacterial superantigens presented by cultured rheumatoid arthritis synoviocytes. Arthritis Rheum. 39:125.[Medline]
35. Cronstein, B. N., M. A. Eberle, H. Gruber, R. Levin. 1991. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc. Natl. Acad. Sci. USA 88:2441.[Abstract/Free Full Text]
36. Brouty-Boyé, D., D. Briard, B. Azzarone, M. C. Lebousse-Kerdilès, D. Clay, C. Pottin-Clémenceau, C. Jasmin. 2001. Effects of human fibroblasts from myelometaplasic and non myelometaplasic hematopoietic tissues on CD34⁺ stem cells. Int. J. Cancer 92:484.[Medline]
37. Skapenko, A., J. Wendler, P. E. Lipsky, J. R. Kalden, H. Schulze-Koops. 1999. Altered memory T cell differentiation in patients with early rheumatoid arthritis. J. Immunol. 163:491.[Abstract/Free Full Text]
38. Corrigall, V. M., E. Solau-Gervais, G. S. Panayi. 2000. Lack of CD80 expression by fibroblast-like synoviocytes leading to anergy in T lymphocytes. Arthritis Rheum. 43:1606.[Medline]
39. Lodolce, J. P., P. R. Burkett, R. M. Koka, D. L. Boone, A. Ma. 2002. Regulation of lymphoid homeostasis by interleukin-15. Cytokine Growth Factor Rev. 13:429.[Medline]
40. Barzegar, C., R. Meazza, R. Pereno, C. Pottin-Clemenceau, M. Scudeletti, D. Brouty-Boye, C. Doucet, Y. Taoufik, J. Ritz, C. Musselli, et al 1998. IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops. Oncogene 16:2503.[Medline]
41. Dubois, S., J. Mariner, T. A. Waldmann, Y. Tagaya. 2002. IL-15R recycles and presents IL-15 in trans to neighboring cells. Immunity 17:537.[Medline]
42. Neely, G. G., S. Epelman, L. L. Ma, P. Colarusso, C. J. Howlett, E. K. Amankwah, A. C. McIntyre, S. M. Robbins, C. H. Mody. 2004. Monocyte surface-bound IL-15 can function as an activating receptor and participate in reverse signaling. J. Immunol. 172:4225.[Abstract/Free Full Text]
43. Sancho, D., M. Yáñez-Mo, R. Tejedor, F. Sánchez-Madrid. 1999. Activation of peripheral blood T cells by interaction and migration through endothelium: role of lymphocyte function-antigen-1/intercellular adhesion molecule-1 and interleukin-15. Blood 93:886.[Abstract/Free Full Text]
44. Lee, J., L. Del Sorbo, S. Uhlig, G. A. Porro, T. Whitehead, S. Voglis, M. Liu, A. S. Slutsky, H. Zhang. 2004. Intercellular adhesion molecule-1 mediates celluar cross-talk between parenchimal and immune cells after lipopolysaccahride neutralization. J. Immunol. 172:608.[Abstract/Free Full Text]
45. Holland, J., T. Owens. 1997. Signaling through intercellular adhesion molecule 1 (ICAM-1) in a B cell lymphoma line: the activation of Lyn tyrosine kinase and the mitogen-activated protein kinase pathway. J. Biol. Chem. 272:9108.[Abstract/Free Full Text]
46. Poudrier, J., T. Owens. 1994. CD54/intercellular adhesion molecule 1 and major histocompatibility complex II signaling induces B cells to express interleukin 2 receptors and complements help provided through CD40 ligation. J. Exp. Med. 179:1417.[Abstract/Free Full Text]
47. Isler, P., E. Vey, J. H. Zhang, J. M. Dayer. 1993. Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1- by monocytic cells: a possible role of CD69. Eur. Cytokine Network 4:15.[Medline]
48. Sancho, D., M. Gomez, F. Viedma, E. Esplugues, M. Gordon-Alonso, M. A. Garcia-Lopez, H. de la Fuente, C. Martinez-A, P. Lauzurica, F. Sanchez-Madrid. 2003. CD69 downregulates autoimmune reactivity through active transforming growth factor- production in collagen-induced arthritis. J. Clin. Invest. 112:872.[Medline]
49. Ziolkowska, M., A. Koc, G. Luszczykiewicz, K. Ksiezopolska-Pietrzak, E. Klimczak, H. Chwalinska-Sadowska, W. Maslinski. 2000. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J. Immunol. 164:2832.[Abstract/Free Full Text]
50. Kotake, S., N. Udagawa, N. Takahashi, K. Matsuzaki, K. Itoh, S. Ishiyama, S. Saito, K. Inoue, N. Kamatani, M. T. Gillespie, et al 1999. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103:1345.[Medline]
51. Chabaud, M., F. Fossiez, J.-L. Taupin, P. Miossec. 1998. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J. Immunol. 161:409.[Abstract/Free Full Text]
52. Chan, E. S., B. N. Cronstein. 2002. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 4:266.[Medline]
53. Cronstein, B. N., R. I. Levin, M. R. Philips, R. Hirschhorn, S. B. Abramson, G. Weissmann. 1992. Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J. Immunol. 148:220.
54. Krauss, K., P. Altevogt. 1999. Integrin leukocyte function-associated antigen-1-mediated cell binding can be activated by clustering of membrane rafts. J. Biol. Chem. 52:36921.
55. Cronstein, B. N., D. Naime, E. Ostad. 1993. The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Invest. 92:2675.
56. Balsa, A., C. Gamallo, E. Martin-Mola, J. Gijon-Banos. 1993. Histologic changes in rheumatoid synovitis induced by naproxen and methotrexate. J. Rheumatol. 20:1472.[Medline]
57. Dolhain, R. J., P. P. Tak, B. A. Dijkmans, P. De Kuiper, F. C. Breedveld, A. M. Miltenburg. 1998. Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br. J. Rheumatol. 37:502.[Abstract/Free Full Text]
58. Kraan, M. C., B. M. de Koster, J. G. R. Elferink, W. Y. Post, F. C. Breedveld, P. P. Tak. 2000. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 43:1488.[Medline]

This article has been cited by other articles:

				I Gonzalez-Alvaro, A M Ortiz, C Dominguez-Jimenez, A Aragon-Bodi, B D. Sanchez, and F Sanchez-Madrid Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway Ann Rheum Dis, October 1, 2009; 68(10): 1644 - 1650. [Abstract] [Full Text] [PDF]

				A. Sattler, U. Wagner, M. Rossol, J. Sieper, P. Wu, A. Krause, W. A. Schmidt, S. Radmer, S. Kohler, C. Romagnani, et al. Cytokine-induced human IFN-{gamma}-secreting effector-memory Th cells in chronic autoimmune inflammation Blood, February 26, 2009; 113(9): 1948 - 1956. [Abstract] [Full Text] [PDF]

				C. N. Tran, S. G. Thacker, D. M. Louie, J. Oliver, P. T. White, J. L. Endres, A. G. Urquhart, K. C. Chung, and D. A. Fox Interactions of T Cells with Fibroblast-Like Synoviocytes: Role of the B7 Family Costimulatory Ligand B7-H3 J. Immunol., March 1, 2008; 180(5): 2989 - 2998. [Abstract] [Full Text] [PDF]

				J. A. M. Wessels, T. W. J. Huizinga, and H.-J. Guchelaar Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis Rheumatology, March 1, 2008; 47(3): 249 - 255. [Abstract] [Full Text] [PDF]

				C. N. Tran, S. K. Lundy, P. T. White, J. L. Endres, C. D. Motyl, R. Gupta, C. M. Wilke, E. A. Shelden, K. C. Chung, A. G. Urquhart, et al. Molecular Interactions between T Cells and Fibroblast-Like Synoviocytes: Role of Membrane Tumor Necrosis Factor-{alpha} on Cytokine-Activated T Cells Am. J. Pathol., November 1, 2007; 171(5): 1588 - 1598. [Abstract] [Full Text] [PDF]

				C. A. Feghali-Bostwick, C. G. Tsai, V. G. Valentine, S. Kantrow, M. W. Stoner, J. M. Pilewski, A. Gadgil, M. P. George, K. F. Gibson, A. M. K. Choi, et al. Cellular and Humoral Autoreactivity in Idiopathic Pulmonary Fibrosis J. Immunol., August 15, 2007; 179(4): 2592 - 2599. [Abstract] [Full Text] [PDF]

				L. Pattacini, B. Casali, L. Boiardi, N. Pipitone, L. Albertazzi, and C. Salvarani Angiotensin II protects fibroblast-like synoviocytes from apoptosis via the AT1-NF-{kappa}B pathway Rheumatology, August 1, 2007; 46(8): 1252 - 1257. [Abstract] [Full Text] [PDF]

				L. Baranda, H. de la Fuente, E. Layseca-Espinosa, D. Portales-Perez, P. Nino-Moreno, G. Valencia-Pacheco, C. Abud-Mendoza, J. Alcocer-Varela, and R. Gonzalez-Amaro IL-15 and IL-15R in leucocytes from patients with systemic lupus erythematosus Rheumatology, December 1, 2005; 44(12): 1507 - 1513. [Abstract] [Full Text] [PDF]

				M.-E. Miranda-Carus, M. Benito-Miguel, M. A. Llamas, A. Balsa, and E. Martin-Mola Human T Cells Constitutively Express IL-15 That Promotes Ex Vivo T Cell Homeostatic Proliferation through Autocrine/Juxtacrine Loops J. Immunol., September 15, 2005; 175(6): 3656 - 3662. [Abstract] [Full Text] [PDF]

				J. H. W. Distler, A. Jungel, L. C. Huber, C. A. Seemayer, C. F. Reich III, R. E. Gay, B. A. Michel, A. Fontana, S. Gay, D. S. Pisetsky, et al. The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles PNAS, February 22, 2005; 102(8): 2892 - 2897. [Abstract] [Full Text] [PDF]

				Robin Goodfellow (43-10) Rheumatology, October 1, 2004; 43(10): 1319 - 1319. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miranda-Carús, M.-E. Articles by Martín-Mola, E. Search for Related Content PubMed PubMed Citation Articles by Miranda-Carús, M.-E. Articles by Martín-Mola, E.